Wednesday, July 8, 2026

Patent intelligence · US

US 6066332

Immediate-effect ibuprofen-containing medicament and its use

expired A61KA61K31/19A61K9/0056A61K9/0095
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 53
Patent details — US 6066332
Jurisdiction
US
Status
expired
Grant date
May 23, 2000
Expiration
May 18, 2020
Applicant
ALFATEC-Pharm GmbH
Claims
28
CPC classes
A61K, A61K31/19, A61K9/0056, A61K9/0095
View on Google Patents ↗

Quick answer

US 6066332 (Immediate-effect ibuprofen-containing medicament and its use) is held by ALFATEC-Pharm GmbH. Status: expired. Granted May 23, 2000. Expires May 18, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ALFATEC-Pharm GmbH
Grant date
Expiration
Claims
28
CPC classes
A61K, A61K31/19, A61K9/0056, A61K9/0095, A61K9/10, A61K9/1658

More from ALFATEC-Pharm GmbH

Related pharmaceutical patents in our USPTO index.

  1. US 12419870

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12410403

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  3. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  5. US 12281329

    Compositions and methods for immune cell modulation in adoptive immunotherapies

    Fate Therapeutics, Inc. · Expires Apr 17, 2045

    granted
  6. US 12275955

    Combining iPSC derived effector cell types for immunotherapy use

    Fate Therapeutics, Inc. · Expires Apr 10, 2045

    granted
  7. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Fate Therapeutics, Inc. · Expires Mar 27, 2045

    granted
  8. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Fate Therapeutics, Inc. · Expires Mar 6, 2045

    granted

Frequently asked questions

What is US patent 6066332?

US 6066332 (Immediate-effect ibuprofen-containing medicament and its use) is held by ALFATEC-Pharm GmbH. Status: expired. Granted May 23, 2000. Expires May 18, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6066332?

ALFATEC-Pharm GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 53 pharmaceutical patents for this assignee.

When does US 6066332 expire?

Our index shows an expiration date of May 18, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.